Paris - Delayed Quote EUR

Implanet S.A. (ALIMP.PA)

0.1240

-0.0045

(-3.50%)

At close: January 17 at 5:27:55 PM GMT+1

IMPLANET Announces 2024 Full-Year Revenue Up 26% to €9.4 Million

BORDEAUX, France & BOSTON, January 14, 2025--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its full-year 2024 revenue and cash position as of December 31, 2024.

Business Wire 4 days ago

ALIMP.PA
-3.50%
IMPLANET Announces Its 2025 Financial Calendar

BORDEAUX, France & BOSTON, January 06, 2025--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2025.

Business Wire 12 days ago

ALIMP.PA
-3.50%
IMPLANET Announces Financing of Around €2 Million

BORDEAUX, France & BOSTON, December 05, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces the implementation of financing with Shanghai Pudong Development Bank ("SPD Bank").

Business Wire last month

ALIMP.PA
-3.50%
IMPLANET announces revenue of €2.3 million as of September 30, 2024, 50% growth

BORDEAUX, France & BOSTON, October 08, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its third-quarter 2024 revenue, ending on September 30, 2024, along with its revenue for the first nine months of 2024.

Business Wire 3 months ago

ALIMP.PA
-3.50%
elliquence and Implanet Form Partnership for US Distribution of Ultrasonic Bone Scalpel Olea in Endoscopic Spine Market

NEW YORK & BORDEAUX, France & CAMBRIDGE, England, September 25, 2024--Regulatory News: elliquence LLC, specializing in advanced minimally invasive surgical technologies, and Implanet (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, have jointly announced a strategic agreement for US distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine sur

Business Wire 3 months ago

ALIMP.PA
-3.50%
Implanet to Co-Exhibit Alongside 8i Robotics’ Next-Gen Robotic Solutions at NASS1 booth #2412 in Chicago

BORDEAUX, France & BOSTON, September 19, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, will share booth #2412 alongside fellow innovator 8i Robotics, pioneering the development of a multi-arm robot system for use in spine and orthopedic surgery, at the NASS meeting to be held from September 25 to 27 in Chicago. Implanet w

Business Wire 3 months ago

ALIMP.PA
-3.50%
IMPLANET Announces Its 2024 Half-year Results

BORDEAUX, France & BOSTON, September 10, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its results for the first half of the current fiscal year, ending June 30, 2024, as approved by the Board of Directors on September 9, 2024.

Business Wire 4 months ago

ALIMP.PA
-3.50%
IMPLANET Reports Revenue of €4.1 Million in the First Half of 2024

BORDEAUX, France & BOSTON, July 09, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its revenue for the first half of 2024.

Business Wire 6 months ago

ALIMP.PA
-3.50%
IMPLANET Receives FDA Clearance for Its New Hybrid Fixation System Jazz Spinal SystemTM

BORDEAUX, France & BOSTON, May 13, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, today announced the Food and Drug Administration (FDA) 510(k) clearance of its new hybrid fixation system Jazz Spinal SystemTM.

Business Wire 8 months ago

IMPZY
Minutes of IMPLANET’s Ordinary General Meeting held on April 25, 2024

BORDEAUX, France & BOSTON, April 25, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, informs its shareholders that its Ordinary General Meeting was held on Thursday April 25, 2024, at 2:00 pm CEST at the Company's registered office, in Martillac.

Business Wire 8 months ago

IMPZY
IMPLANET Reports its 2024 First-Quarter Revenue

BORDEAUX, France & BOSTON, April 09, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, today announces its revenue for the first quarter of 2024.

Business Wire 9 months ago

IMPZY
IMPLANET Reports Its 2023 Full-Year Results

BORDEAUX, France & BOSTON, March 06, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plan), a medical technology company specialized in implants for orthopedic surgery and the distribution of technological medical equipment, today announced its 2023 full-year results, as of December 31, 2023, as approved by the Board of Directors on March 5, 2024.

Business Wire 10 months ago

IMPZY
Implanet Announces the Success of Its Capital Increase

BORDEAUX, France & BOSTON, February 02, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), (the "Company"), a medical technology company specialized in implants for orthopedic surgery and the distribution of technological medical equipment, announces the success of the capital increase in cash with preferential subscription rights for shareholders announced on January 4, 2024 (the "Capital Increase"). This operation raised €5.5 mill

Business Wire 11 months ago

IMPZY
Implanet Announces the Appointment of Max W. Painter as Vice-President and General Manager of its US Subsidiary

BORDEAUX, France & BOSTON, January 25, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, announced the appointment of Max W. Painter as VP & General Manager of Implanet America. In this position, he will lead Implanet America, with the aim of optimizing its organizational structure to accelerate the

Business Wire 11 months ago

IMPZY

Performance Overview

Return	ALIMP.PA	CAC 40
YTD	+10.71%	+5.42%
1-Year	+104.28%	+4.21%
3-Year	-59.74%	+7.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Implanet S.A. (ALIMP.PA)

IMPLANET Announces 2024 Full-Year Revenue Up 26% to €9.4 Million

IMPLANET Announces Its 2025 Financial Calendar

IMPLANET Announces Financing of Around €2 Million

IMPLANET announces revenue of €2.3 million as of September 30, 2024, 50% growth

elliquence and Implanet Form Partnership for US Distribution of Ultrasonic Bone Scalpel Olea in Endoscopic Spine Market

Implanet to Co-Exhibit Alongside 8i Robotics’ Next-Gen Robotic Solutions at NASS1 booth #2412 in Chicago

IMPLANET Announces Its 2024 Half-year Results

IMPLANET Reports Revenue of €4.1 Million in the First Half of 2024

IMPLANET Receives FDA Clearance for Its New Hybrid Fixation System Jazz Spinal SystemTM

Minutes of IMPLANET’s Ordinary General Meeting held on April 25, 2024

IMPLANET Reports its 2024 First-Quarter Revenue

IMPLANET Reports Its 2023 Full-Year Results

Implanet Announces the Success of Its Capital Increase

Implanet Announces the Appointment of Max W. Painter as Vice-President and General Manager of its US Subsidiary

Performance Overview